2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. DNA/RNA Synthesis

DNA/RNA Synthesis

DNA/RNA Synthesis

Related Products

PDF 1.61 MB

RNA synthesis, which is also called DNA transcription, is a highly selective process. Transcription by RNA polymerase II extends beyond RNA synthesis, towards a more active role in mRNA maturation, surveillance and export to the cytoplasm.

Single-strand breaks are repaired by DNA ligase using the complementary strand of the double helix as a template, with DNA ligase creating the final phosphodiester bond to fully repair the DNA.DNA ligases discriminate against substrates containing RNA strands or mismatched base pairs at positions near the ends of the nickedDNA. Bleomycin (BLM) exerts its genotoxicity by generating free radicals, whichattack C-4′ in the deoxyribose backbone of DNA, leading to opening of the ribose ring and strand breakage; it is an S-independentradiomimetic agent that causes double-strand breaks in DNA.

First strand cDNA is synthesized using random hexamer primers and M-MuLV Reverse Transcriptase (RNase H). Second strand cDNA synthesis is subsequently performed using DNA Polymerase I and RNase H. The remaining overhangs are converted into blunt ends using exonuclease/polymerase activity. After adenylation of the 3′ ends of DNA fragments, NEBNext Adaptor with hairpin loop structure is ligated to prepare the samples for hybridization. Cell cycle and DNA replication are the top two pathways regulated by BET bromodomain inhibition. Cycloheximide blocks the translation of mRNA to protein.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-120118
    Metarrestin
    		Inhibitor 99.90%
    Metarrestin (ML246) is an orally active, first-in-class and specific perinucleolar compartment inhibitor. Metarrestin disrupts the nucleolar structure and inhibits RNA polymerase (Pol) I transcription, at least in part by interacting with the translation elongation factor eEF1A2. Metarrestin blocks metastatic development and extends survival in mouse cancer models.
    Metarrestin
  • HY-16350
    BOLD-100
    		Inhibitor
    BOLD-100 (NKP-1339; IT-139) is the first-in-class ruthenium-based anticancer agent in development against solid cancer with limited side effects. BOLD-100 induces G2/M cell cycle arrest, blockage of DNA synthesis, and induction of apoptosis via the mitochondrial pathway. BOLD-100 has a high tumor targeting potential, strongly binds to serum proteins such as albumin and transferrin and activates in the reductive tumor milieu.
    BOLD-100
  • HY-15588
    L189
    		Inhibitor ≥98.0%
    L189 is a DNA ligase inhibitor. L189 has inhibition effect for DNA Ligase I, III and IV with IC50 values of 5 μM, 9 μM and 5 μM, respectively. L189 has no cytotoxicity and individually increase cell death. L189 can be used for the research of cancer.
    L189
  • HY-148772
    PTC258
    		Modulator 98.72%
    PTC258 is a specific and orally active splicing modulator of Elongator complex protein 1 gene (ELP1). PTC258 increases the expression of ELP1 in vitro and in vivo. PTC258 is well tolerated in mouse model.
    PTC258
  • HY-162289
    FAZ-3780
    		98.91%
    FAZ-3780 (compound G3Ib) is an inhibitor of binding to the NTF2L domain of G3BP1/2 that binds to G3BP1 with a Kd of 0.15 μM. FAZ-3780 targets the protein-protein interaction domain of G3BP1/2 and specifically inhibits co-condensation of G3BP1, caprin 1, and RNA in vitro.
    FAZ-3780
  • HY-18649
    Galidesivir hydrochloride
    		Inhibitor 99.89%
    Galidesivir (BCX4430) hydrochloride, an adenosine analog and a direct-acting antiviral agent, disrupts viral RNA-dependent RNA polymerase (RdRp) activity. Galidesivir hydrochloride is active in vitro against many RNA viral pathogens, including the filoviruses and emerging infectious agents such as MERS-CoV, SARS-CoV, and SARS-CoV-2. Galidesivir hydrochloride inhibits some negative-sense RNA viruses with EC50s ranging from ~3 to ~68 μM.
    Galidesivir hydrochloride
  • HY-135902A
    Synucleozid hydrochloride
    		Inhibitor 98.23%
    Synucleozid hydrochloride (NSC 377363 hydrochloride) is a potent inhibitor of the?SNCA?mRNA?that encodes α-synuclein protein. Synucleozid selectively?targets the?α-synuclein?mRNA 5′ UTR at the designed IRE site, decreases the amount of?SNCA?mRNA loaded into polysomes and thereby inhibits?SNCA?translation. Synucleozid has the potential for the investigation of Parkinson’s disease.
    Synucleozid hydrochloride
  • HY-10443
    Balapiravir
    		Inhibitor
    Balapiravir (Ro 4588161; R1626) is an orally active proagent of a nucleoside analogue inhibitor of the RNA-dependent RNA polymerase (RdRp) of HCV (R1479; 4'-Azidocytidine). Balapiravir has anti-HCV activity. Balapiravir is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
    Balapiravir
  • HY-16965
    TH287
    		Inhibitor 98.29%
    TH287 is a potent and selective inhibitor of MTH1, with an IC50 of 0.8 nM. TH287 is highly selective towards MTH1, with no relevant inhibition of MTH2, NUDT5, NUDT12, NUDT14, NUDT16, dCTPase, dUTPase and ITPA at 100 μM. TH287 could act as a chemotherapeutic agent for cancer research.
    TH287
  • HY-B1907
    Rifamycin sodium
    		Inhibitor 99.56%
    Rifamycin sodium (Rifamycin SV monosodium) is an orally active ansamycin antibiotic. Rifamycin sodium inhibits DNA-dependent RNA synthesis. Rifamycin sodium has antibacterial activity against Mycobacterium tuberculosis. Rifamycin sodium interferes with hepatic bile acid metabolism. Rifamycin sodium has anti-inflammatory effects. Rifamycin sodium can be used in the study of Mycobacterium tuberculosis, Bacteroides fragilis infection, and Lipopolysaccharide (HY-D1056B3)-induced inflammation.
    Rifamycin sodium
  • HY-103019B
    (-)-Enitociclib
    		Inhibitor 99.85%
    (-)-Enitociclib ((R)-Enitociclib) is an enantiomer of Enitociclib (HY-103019E) with an optical rotation of (-). Enitociclib is a selective CDK9 inhibitor and apoptosis inducer. Enitociclib inhibits CDK9 activity and reduces the phosphorylation of Ser2 in the carboxyl-terminal domain (CTD) of RNA polymerase Pol II, thereby downregulating the transcription of key oncogenes such as MYC and MCL1. Enitociclib has anti-proliferative activity targeting MYC+ lymphoma and multiple myeloma (MM) cells, and has synergistic effects with Bortezomib (HY-10227) and Lenalidomide (HY-A0003), and can be used in the research of hematological malignancies.
    (-)-Enitociclib
  • HY-134103A
    ddGTP trisodium
    		Inhibitor 98.01%
    ddGTP (2′,3′-Dideoxyguanosine 5′-triphosphate) trisodium is one of 2',3'-dideoxyribonucleoside 5'-triphosphates (ddNTPs) that acts as chain-elongating inhibitor of DNA polymerase for DNA sequencing. ddGTP trisodium acts as an inhibitor or a substrate for DNA polymerase α.
    ddGTP trisodium
  • HY-137463
    AG-636
    		Inhibitor 98.25%
    AG-636 is a potent, reversible, selective and orally active dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 of 17 nM. AG-636 has strong anticancer effects.
    AG-636
  • HY-144256
    CHD1Li 6.11
    		Inhibitor 99.54%
    CHD1Li 6.11 is a potent oncogenic CHD1L inhibitor (IC50=3.3 µM for cat-CHD1L recombinant protein). CHD1Li 6.11 is an orally bioavailable antitumor agent, significantly reducing the tumor volume of CRC xenografts generated from isolated quasi mesenchymal cells (M-phenotype), which possess enhanced tumorigenic properties.
    CHD1Li 6.11
  • HY-153916
    TCRS-417
    		99.13%
    TCRS-417 (T417) is a small-molecular inhibitor for PBX1. TCRS-417 can directly block PBX1-binding to DNA (IC50 = 6.58 μM), and affects PBX1 transcription. TCRS-417 is able to hammer out the stemness traits of Carboplatin (HY-17393)-resistant (CR) cells to revert to a differentiated status through tacking PBX1 signaling cascade. TCRS-417 significantly suppresses self-renewal and proliferation of cancer cells expressing high levels of PBX1. TCRS-417 can decrease the mRNA levels of FOXM1, NEK2, and E2F2 in cancer cell lines. TCRS-417 is selectively toxic against chr1q-amp myeloma and solid tumor cells.
    TCRS-417
  • HY-149887
    H3B-968
    		98.22%
    H3B-968 is the ATP-competitive inhibitor of Werner syndrome protein (WRN) with an IC50 of about 10 nM.
    H3B-968
  • HY-W017443
    L-Asparagine monohydrate
    		99.77%
    L-Asparagine monohydrate is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine monohydrate can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia.
    L-Asparagine monohydrate
  • HY-101400A
    Deoxycytidine triphosphate (trisodium) solution (100mM)
    		Activator 99.46%
    Deoxycytidine triphosphate trisodium (dCTP trisodium) solution (100mM) is a nucleoside triphosphate that can be used for DNA synthesis. Deoxycytidine triphosphate trisodium salt has many applications, such as real-time PCR, cDNA synthesis, and DNA sequencing.
    Deoxycytidine triphosphate (trisodium) solution (100mM)
  • HY-105336
    3-Deazauridine
    		Inhibitor 99.67%
    3-Deazauridine (NSC 126849) is a uridine analogue. 3-Deazauridine competitively inhibits cytidine triphosphate synthase to inhibit the biosynthesis of cytidine-5'-triphosphate. 3-Deazauridine acts synergistically with several antineoplastic agents, acting as a biological response modifier.
    3-Deazauridine
  • HY-105099
    Rifalazil
    		Inhibitor 99.64%
    Rifalazil (KRM-1648; ABI-1648), a rifamycin derivative, inhibits the bacterial DNA-dependent RNA polymerase and kills bacterial cells by blocking off the β-subunit in RNA polymerase. Rifalazil (KRM-1648; ABI-1648) is an antibiotic, exhibits high potency against mycobacteria, gram-positive bacteria, Helicobacter pylori, C. pneumoniae and C. trachomatis with MIC values from 0.00025 to 0.0025 μg/ml. Rifalazil (KRM-1648; ABI-1648) has the potential for the treatment of Chlamydia infection, Clostridium difficile associated diarrhea (CDAD), and tuberculosis (TB).
    Rifalazil
Cat. No. Product Name / Synonyms Application Reactivity